Future Science OA最新文献

{"title":"Patient perceptions of integrated cardiovascular care in primary healthcare settings in Kazakhstan.","authors":"Yevgenii Blum, Dana Amanova, Vilen Molotov-Luchanskiy, Bakhyt Kosherova","doi":"10.1080/20565623.2026.2733700","DOIUrl":"10.1080/20565623.2026.2733700","url":null,"abstract":"<p><strong>Aims: </strong>Cardiovascular diseases remain a major cause of morbidity and mortality in Kazakhstan. This study aimed to evaluate patient perceptions of integrated cardiovascular care in primary healthcare (PHC) and identify factors associated with satisfaction with outpatient cardiovascular services.</p><p><strong>Materials and methods: </strong>A cross-sectional survey included 268 patients receiving outpatient care for cardiovascular diseases or risk factors. A validated questionnaire assessed multidisciplinary team (MDT) involvement, medication support, daycare hospital use, healthcare professional support, treatment adherence, and psychosocial factors. Data were analyzed using descriptive statistics, Pearson's chi-square test, and Firth-penalized logistic regression.</p><p><strong>Results: </strong>Of 268 participants, 220 (82.1%; 95% CI, 77.1-86.3%) were satisfied with outpatient cardiovascular care, while only 12.7% were aware of MDT involvement. Satisfaction was associated with educational level (p = 0.019), treatment adherence (p < 0.001), medication support awareness (p < 0.001), MDT awareness (p = 0.015), daycare hospital use (p = 0.009), psychological concerns (p < 0.001), and nurse support (p < 0.001).</p><p><strong>Conclusions: </strong>Satisfaction was associated primarily with organizational, behavioral, and psychosocial aspects of care. Limited MDT awareness suggests that integrated-care structures may not always be perceived by patients as coordinated care.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2733700"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13596899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing community pharmacists' understanding, attitudes, self-confidence, and obstacles in patient-centered communication.","authors":"Ammar Abdulrahman Jairoun, Sabaa Saleh Al-Hemyari, Faris El-Dahiyat, Moyad Shahwan, Sa'ed H Zyoud, Eman Abu-Gharbieh, Fahad S Alshehri, Alanood S Algarni, Nasser M Alorfi","doi":"10.1080/20565623.2026.2615617","DOIUrl":"10.1080/20565623.2026.2615617","url":null,"abstract":"<p><strong>Background: </strong>Enhancing communication practices among pharmacy professionals is essential for patient-centered care.</p><p><strong>Methods and materials: </strong>A cross-sectional survey was conducted among a random sample of licensed pharmacists from June 2022 to January 2023. Out of 640 pharmacists, 577 participated in the study, yielding a response rate of 90.2%. Participants completed a questionnaire covering demographics and their knowledge, attitudes, self-efficacy, and perceived barriers regarding PCC. Multivariate logistic regression identified factors influencing PCC-related scores.</p><p><strong>Results: </strong>The results indicated good knowledge, attitudes, and self-efficacy toward PCC. Higher PCC scores were associated with older age, postgraduate education, chain pharmacy employment, leadership roles, greater experience, and international or regional education. Key barriers included workload, staff shortages, time constraints, and an unsupportive work environment.</p><p><strong>Conclusion: </strong>The findings, based on self-reported perceptions, suggest standard communication guidelines and awareness programs are warranted to facilitate PCC integration and enhance pharmacy professionals' confidence and skills in patient-centered care.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2615617"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12867421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146085485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaginal vitamin D for Genitourinary syndrome of menopause: a cohort study and literature review.","authors":"Christopher Massaad, Rawan Abdul Razzak, Kariman Ghazal","doi":"10.1080/20565623.2026.2621650","DOIUrl":"10.1080/20565623.2026.2621650","url":null,"abstract":"<p><strong>Background: </strong>Genitourinary syndrome of menopause (GSM) is a condition resulting from hypoestrogenism, characterized by symptoms such as vaginal dryness, irritation, urinary urgency, and sexual dysfunction. While conventional treatments include local estrogen therapy and non-hormonal alternatives, evidence suggests a therapeutic role for vitamin D.</p><p><strong>Research design and methods: </strong>This study assessed the efficacy of vaginal vitamin D supplementation in alleviating GSM symptoms and evaluated clinical factors. Two cohorts were analyzed: 110 postmenopausal women with GSM symptoms and 39 participants aged 35-85 for age-related analysis. Data were analyzed using SPSS Version 26.</p><p><strong>Results: </strong>Findings revealed associations between age and pelvic exam outcomes, with older women more likely to exhibit atrophic cervix, while younger participants presented with cervicitis. Delivery mode was also significantly correlated with pelvic exam findings (<i>p</i> = 0.040). Notably, all patients receiving vitamin D (10/10) achieved symptom remission at 3 months versus 34% (10/29) in controls (<i>p</i> = 0.00044), though limited by the small <i>n</i> and observational design of the study. Extended treatment showed 96.7% remission in vitamin D vs. 62.9% controls (aRR = 1.26, 95% CI 1.05-1.50, <i>p</i> = 0.024. Vitamin D + probiotics yielded 100% remission.</p><p><strong>Conclusions: </strong>These support vitamin D as effective non-hormonal GSM therapy, pending larger RCTs.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2621650"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12867353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The therapeutic potential of targeting LYAR in gastric cancer.","authors":"Kai Qin, Guo-Qiang Chen, Jing-Wen Ling, Yu-Feng Li, Qi Li, Dong-Ming Li, Bin Li, Jian-Di Li, Ke-Jun Wu, Rong-Quan He, Di-Yuan Qin, Yi-Wu Dang, Gang Chen, Yu-Lu Tang","doi":"10.1080/20565623.2025.2610163","DOIUrl":"10.1080/20565623.2025.2610163","url":null,"abstract":"<p><strong>Aim: </strong>To investigate the expression of Ly1 antibody-reactive clone (LYAR) in gastric cancer (GC) tissues and predict potential drugs targeting its sensitivity.</p><p><strong>Methods: </strong>We assessed the standardized mean difference (SMD) of LYAR mRNA expression across 20 GC datasets (1,804 GC samples, 858 normal tissues) using multi-center high-throughput data, in-house immunohistochemistry, and CCLE cell expression data. Clinical and pathological relevance of LYAR was evaluated using metrics such as receiver operating characteristic curve, sensitivity, specificity, and likelihood ratios. Additionally, upstream transcriptional regulation and enrichment analyses were performed, and drug sensitivity analysis identified potential drugs for high LYAR expression.</p><p><strong>Results: </strong>LYAR expression was significantly upregulated in GC (SMD: 1.20, 95% CI: 0.89-1.51). The area under the curve was 0.89 (95% CI: 0.86-0.92), with sensitivity 0.74 (95% CI: 0.66-0.81) and specificity 0.89 (95% CI: 0.82-0.94). MYC potentially enhances LYAR expression, promoting GC progression. High LYAR expression indicates sensitivity to AZD compounds.</p><p><strong>Conclusion: </strong>LYAR overexpression promotes GC progression and tumorigenesis, suggesting its potential as a therapeutic target.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2610163"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12795265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145943222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting FMO3 suppresses the malignant phenotype of colorectal cancer: evidence from bioinformatics to functional experiments.","authors":"Rong Su, Cuncun Huang, Zhe Jing, Shuping Qiu, Lihua Shao, Tinghong Jiao, Hongwei Wang, Hailong Li","doi":"10.1080/20565623.2026.2629346","DOIUrl":"10.1080/20565623.2026.2629346","url":null,"abstract":"<p><strong>Aims: </strong>Flavin-containing monooxygenase 3 (FMO3) is a key metabolic enzyme involved in endogenous metabolism; however, its role in colorectal cancer (CRC) remains poorly understood. This study aimed to investigate the expression pattern, biological function, and potential clinical relevance of FMO3 in CRC.</p><p><strong>Materials and methods: </strong>Publicly available transcriptomic datasets were analyzed to assess FMO3 expression and its association with clinical characteristics. Immunohistochemistry and in vitro functional assays were performed to evaluate the effects of FMO3 on CRC cell proliferation, cell-cycle progression, migration, and invasion. Bioinformatics analyses were used to explore potential signaling pathways and immune-related associations.</p><p><strong>Results: </strong>FMO3 was significantly upregulated in CRC tissues and cell lines and was associated with unfavorable clinicopathological features and poor prognosis. Silencing of FMO3 inhibited CRC cell proliferation by inducing G0/G1 cell-cycle arrest and suppressed migration and invasion by reversing epithelial-mesenchymal transition-related phenotypes. Mechanistically, FMO3 depletion attenuated PI3K/AKT signaling activity. In addition, FMO3 expression was correlated with immune cell infiltration patterns and immune checkpoint-related molecules.</p><p><strong>Conclusions: </strong>FMO3 promotes malignant progression of colorectal cancer and may serve as a potential biomarker and therapeutic target. Further in vivo and mechanistic studies are warranted to validate these findings.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2629346"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution and future directions of bispecific antibodies in breast cancer: a global clinical trial landscape analysis.","authors":"Xubin Zhu, Shiyou Luo, Yiheng Li","doi":"10.1080/20565623.2026.2703784","DOIUrl":"10.1080/20565623.2026.2703784","url":null,"abstract":"","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2703784"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148455580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Side-level versus patient-level evaluation in four-view mammography classification: a comprehensive benchmark on the CMMD dataset.","authors":"Mohamed A Mabrok","doi":"10.1080/20565623.2026.2681575","DOIUrl":"10.1080/20565623.2026.2681575","url":null,"abstract":"<p><strong>Background: </strong>Deep learning for mammographic image classification yields impressive performance metrics, but inconsistent evaluation methodologies-specifically whether results are reported at the independent side level or the bilateral patient level-make cross-study comparisons unreliable. The aim of this study was to quantify, on a single dataset and with a uniform training recipe, how much of the reported performance is determined by evaluation granularity rather than by model architecture.</p><p><strong>Materials & methods: </strong>We benchmarked six backbone architectures (ResNet-18, ResNet-50, EfficientNet-B0, DenseNet-121, ConvNeXt-Tiny, ViT-B/16) crossed with three multi-view fusion strategies (concatenation, bilateral asymmetry, cross-view spatial attention) on the biopsy-confirmed Chinese Mammography Database (CMMD; 706 four-view patients), using five-fold patient-level stratified cross-validation. Sixteen configurations completed training for both binary malignancy diagnosis and five-class BI-RADS assessment. We report side-level and patient-level metrics; statistical analyses include 5-fold Wilcoxon signed-rank tests, DeLong's paired AUC test on pooled per-case scores, and bootstrap 95% confidence intervals.</p><p><strong>Results: </strong>Side-level AUC exceeded patient-level AUC by an average of 17.5 percentage points (range 12.7-22.4), an effect that dwarfs the absolute differences observed between CNN backbones (<3 AUC points). DeLong tests resolved approximately half of all CNN-vs-CNN pairwise comparisons at p<0.05 despite small effect sizes, whereas ViT-B/16 underperformed every CNN variant by 8-10% AUC despite having 6-10× more parameters. Patient-level multi-class BI-RADS evaluation under the standard probability-averaging aggregation rule returned a degenerate macro-AUC of exactly 0.000-a property of the metric/aggregation pair, not of the models-and three concrete alternative aggregators are proposed. The extreme patient-level malignancy prevalence intrinsic to this biopsy-confirmed cohort (96.2%) rendered all models unable to identify non-malignant patients at the patient level.</p><p><strong>Conclusion: </strong>Reporting methodology, evaluation granularity, and dataset composition are compounding confounds in mammography classification research. Absolute performance numbers reported on CMMD should not be extrapolated to population screening settings, where prevalence is several orders of magnitude lower; studies should report both side-level and patient-level metrics with mutually consistent label/aggregation rules, and characterise performance using confidence intervals or paired statistical tests rather than fold-level Wilcoxon alone.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2681575"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148217116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RIRS vs PCNL in treating lower-pole renal stones: a comparative clinical outcome study.","authors":"Samer Al-Rawashdah","doi":"10.1080/20565623.2026.2646277","DOIUrl":"10.1080/20565623.2026.2646277","url":null,"abstract":"<p><strong>Purpose: </strong>The reduced-pole renal stones with a length of 1-2 cal have a special anatomical problem, which could also influence the degree of efficacy of treatment and incidence rates. Retrograde intrarenal surgery (RIRS) and percutaneous nephrolithotomy (PCNL) are the two popular techniques of their treatment but the best method is yet questionable. The purpose of the research was to compare the perioperative outcome, complication profile, and stone-free rates between RIRS and PCNL as the forms of treatment of the lower-pole renal stones.</p><p><strong>Methods: </strong>This study was designed as a retrospective multicenter comparative clinical outcome study. There was a total 177 adult patient, 1-2 cm solitary lower pole renal stones, 85 patients undergoing RIRS and 92 patients undergoing PCNL. The preoperative characteristics of the stones and anatomical parameters were estimated by non-contrast computed tomography. The intraoperative variables and the postoperative recovery outcomes and complications are noted. At 3 months, non-contrast CT was checked to identify if the patient was stone-free or not. The determination of complications was done using the Clavien-Dindo system. The parametric and nonparametric tests were conducted to perform a statistical comparison of the results obtained and the significance was established at p < 0.05.</p><p><strong>Results: </strong>Both groups were similar for baseline demographic, clinical, stone-related and anatomical characteristics. PCNL showed a much high stone free rate at 3 months than in RIRS (93.5 vs 78.8; p = 0.01). Nonetheless, the RIRS was associated with a much shorter period of operation, decreased fluoroscopy level, lesser pain rating postop, decrease in hemoglobin levels, and decreased hospitalization (all p < 0.001). The overall rates of complications were much more increased in PCNL in comparison with the control (39.1 vs 16.5; p = 0.002), such aspects as febrile episodes, urinary tract infection, blood transfusion, major complications (Clavien-Dindo grade ≥ III), and 30-day readmissions. The increased need for auxiliary procedures and re-interventions was related to RIRS.</p><p><strong>Conclusion: </strong>PCNL is better used in the treatment of inferior pole renal stones not exceeding 1-2 cm in size and RIRS is better in terms of perioperative profile (lowest morbidity, faster recovery). The selection of treatment must be made on a case-by-case basis with a trade-off between the greatest clearance of the stone and the risk inherent in the treatment and characteristics of the patient.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2646277"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147528246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacotherapy for online behavioral addictions: a systematic review.","authors":"Jennifer J Park, Bryan B Chen, Marc N Potenza","doi":"10.1080/20565623.2026.2681577","DOIUrl":"10.1080/20565623.2026.2681577","url":null,"abstract":"<p><strong>Introduction: </strong>In response to the increasing prevalence of online behavioral addictions, researchers have investigated various treatment approaches, including pharmacotherapies. This systematic review aimed to summarize pharmacotherapeutic studies of online behavioral addictions.</p><p><strong>Methods: </strong>PubMed, MEDLINE, and Embase were searched to identify randomized controlled trials or quasi-experimental studies of pharmacotherapy for online behavioral addictions. Studies were excluded if they only targeted offline behavioral addictions. Study findings were summarized, and the Effective Public Health Practice Project Quality Assessment Tool was used for quality assessment.</p><p><strong>Results: </strong>This systematic review included 20 studies (1016 participants). Bupropion, selective serotonin reuptake inhibitors (SSRIs), and opioid receptor antagonists were most frequently studied and showed preliminary promise in reducing symptom severity. Many pharmacotherapeutic studies addressed co-occurring concerns, such as depression.</p><p><strong>Conclusions: </strong>Pharmacotherapies for online behavioral addictions appear promising, but the evidence base was limited by small samples, few randomized controlled trials, and short follow-up periods. Given preliminary support for psychotherapy + pharmacotherapy for problematic gaming, future research may evaluate the efficacy of combined treatment for a broader range of online behavioral addictions. Future research should also investigate pharmacotherapies for emerging problematic online behaviors, such as AI-based sexual engagement and problematic cryptocurrency trading.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2681577"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13251523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148198433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound-guided injection strategies for lateral epicondylitis: a multicenter randomized comparison of corticosteroid, platelet-rich plasma, and ozone.","authors":"Seyed Ahmad Raeissadat, Davood Khavari Ardestani, Seyyede Elahe Mousavikhah, Masume Bayat, Marzieh Babaee, Mahfam PourAzin","doi":"10.1080/20565623.2026.2644326","DOIUrl":"10.1080/20565623.2026.2644326","url":null,"abstract":"<p><strong>Objective: </strong>To compare the effectiveness of ultrasound-guided injections of corticosteroid, platelet-rich plasma (PRP), and ozone for treating chronic lateral epicondylitis.</p><p><strong>Methods: </strong>This multi-center, three-arm, assessor-blinded, randomized controlled trial enrolled 90 patients with chronic lateral epicondylitis. Participants were randomized in a 1:1:1 ratio to receive a single ultrasound-guided injection of either methylprednisolone, low-leukocyte PRP, or medical ozone. The primary outcomes were pain on the visual analog scale (VAS), function via the Mayo Elbow Performance Index (MEPI), and the pressure pain threshold (PPT), assessed at baseline, 8 weeks, and 6 months.</p><p><strong>Results: </strong>Eighty of the 90 randomized patients completed the study. All three treatment groups demonstrated statistically significant improvements from baseline across all primary outcome measures at both the 8-week and 6-month follow-ups (<i>p</i> < .05 for all). However, the primary comparative analysis revealed no statistically significant differences between the corticosteroid, PRP, and ozone groups for any outcome measure at any follow-up time point (<i>p</i> > .05 for all between-group comparisons).</p><p><strong>Conclusion: </strong>Ultrasound-guided injections of corticosteroid, low-leukocyte PRP, and ozone are all effective treatments for improving pain and function in patients with chronic lateral epicondylitis at 6 months. As no single agent proved statistically superior, the choice of therapy should be guided by a process of shared decision-making that considers factors such as patient preference, cost, and desired timeline for relief.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"12 1","pages":"2644326"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13078189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147672405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}